This question usually arrives in one of two forms. Sometimes it is a patient in her sixties who was just diagnosed with osteoporosis and assumes her implant plans are over: "My bones are thinning — surely a titanium screw won't hold?" Other times it is a patient who has been taking Fosamax for years and read something alarming online about jawbone death. Both versions deserve a careful, honest answer, because both contain a kernel of truth wrapped in a great deal of unnecessary fear.
Here is the short version: osteoporosis, by itself, does not disqualify you from dental implants. The research on implant survival in osteoporotic patients is genuinely reassuring. The part that requires real planning is not your bone density — it is the medications used to treat it, particularly bisphosphonates and denosumab, which change how your jawbone remodels and carry a small but real risk of a complication called medication-related osteonecrosis of the jaw. This article walks through what the evidence actually shows, what each drug means for surgery, and how I plan implant treatment for these patients at my practice in Costa Mesa.
The Short Answer
Most people with osteoporosis can safely receive dental implants, and studies show survival rates comparable to patients with normal bone density. Osteoporotic bone heals more slowly, so protocols are adjusted: gentler site preparation, longer healing before the implant bears load, and careful CBCT planning. The medications matter more than the diagnosis — oral bisphosphonates at osteoporosis doses carry a very low risk of jaw osteonecrosis (well under 1%), rising with more than four years of use; denosumab (Prolia) requires surgery to be timed within its six-month dosing cycle; and high-dose IV antiresorptives for cancer are a different situation entirely, where elective implants are generally avoided. Never stop a bone medication on your own — the decision belongs to your physician and your surgeon together.
Osteoporosis and Your Jaw: What's Actually Happening
Osteoporosis is a systemic skeletal condition in which bone is broken down faster than it is rebuilt, leaving the skeleton less dense and more fracture-prone. It is diagnosed with a DEXA scan and expressed as a T-score: -2.5 or below is osteoporosis, between -1.0 and -2.5 is osteopenia. Roughly ten million Americans have osteoporosis, most of them postmenopausal women, because the drop in estrogen accelerates bone loss.
Your jaw is part of that skeleton, so it participates in the same process — but not uniformly. The jaw contains two kinds of bone: a dense outer shell of cortical bone and a spongy inner network of trabecular bone. Osteoporosis affects trabecular bone most, which is why the regions that were already the softest — especially the back of the upper jaw — tend to be where osteoporotic changes show up on a scan. The front of the lower jaw, dense to begin with, usually remains excellent implant territory even in patients with significant osteoporosis.
Two other points are worth knowing. First, osteoporosis and gum disease are correlated: low systemic bone density is associated with more alveolar bone loss around teeth, and the two conditions share risk factors like age, smoking, and inflammation. If you have both, treating the periodontal disease comes first, since placing an implant into an infected mouth is a recipe for failure regardless of bone density. Second, jawbone loss after tooth extraction happens in everyone — osteoporotic or not — which I covered in detail in my article on what causes bone loss in the jaw. Osteoporosis can compound that loss, but it is rarely the main driver.
What the Research Shows About Implant Success in Osteoporotic Bone
This is where the news is better than most patients expect. Multiple systematic reviews and meta-analyses comparing implant outcomes in osteoporotic versus non-osteoporotic patients have reached the same broad conclusion: implant survival rates are similar between the two groups. Osteoporosis was once listed among the relative contraindications to implant therapy; decades of clinical data have quietly retired that idea.
The honest caveats:
- Osseointegration takes longer. Implants succeed by fusing to living bone — a process that depends on bone cells remodeling around the titanium surface. In low-density bone, that biology runs slower, so I extend healing time before the implant carries chewing force.
- Initial stability can be harder to achieve. Soft, sparse trabecular bone grips an implant less firmly on the day of surgery. This is a surgical-technique problem with surgical-technique solutions, which I describe below.
- Slightly more marginal bone loss. Some studies report modestly greater bone loss around implants in osteoporotic patients over the years — a reason for diligent maintenance, not a reason to avoid treatment.
- Immediate loading deserves caution. "Teeth in a day" protocols depend on high initial stability. In significantly osteoporotic bone, I am more conservative about same-day loading and more inclined to let the implant heal undisturbed first.
In practice, the osteoporosis itself changes the how and the when of implant treatment — not the whether.
The Real Issue: Bone Medications and MRONJ
Now to the part your oral surgeon or periodontist genuinely needs to think hard about. The drugs that treat osteoporosis work mostly by slowing bone breakdown — they are called antiresorptives. Slowing bone turnover strengthens your hip and spine, but bone turnover is also how your jaw heals after surgery. In a small number of patients, heavily suppressed jawbone loses its ability to repair itself after trauma or surgery, and an area of bone becomes exposed and fails to heal. This is medication-related osteonecrosis of the jaw (MRONJ).
MRONJ is real, and it is serious when it occurs. It is also — and this is the part the internet reliably omits — rare at osteoporosis doses. The risk depends enormously on which drug, what dose, and for how long:
| Medication | How it works | What it means for implant surgery |
|---|---|---|
| Oral bisphosphonates alendronate (Fosamax), risedronate (Actonel), ibandronate (Boniva) |
Bind into bone mineral and suppress the cells that break bone down; remain in the skeleton for years | MRONJ risk after oral surgery is very low — commonly cited at a fraction of one percent. Risk increases after roughly 4+ years of use. Implants are routinely and successfully placed in these patients with informed consent and careful technique. |
| IV bisphosphonates for osteoporosis zoledronic acid (Reclast), once yearly |
Same mechanism, delivered intravenously at osteoporosis doses | Risk remains low at osteoporosis dosing, though higher than oral pills; planning and physician coordination are essential. |
| Denosumab (Prolia), injected every 6 months |
An antibody that blocks bone-resorbing cells; effect wears off between doses rather than accumulating | MRONJ risk is comparable to or slightly higher than bisphosphonates. Because the effect is cyclical, surgery is often timed late in the dosing interval. Never delay a dose on your own — stopping denosumab abruptly causes rebound bone loss and vertebral fracture risk. |
| High-dose IV antiresorptives for cancer zoledronic acid (Zometa), denosumab (Xgeva) |
Same drug classes at far higher, more frequent dosing to protect bone from cancer spread | A different risk category entirely — MRONJ rates in the range of several percent. Elective implant surgery is generally avoided; tooth-preservation strategies come first. |
| Anabolic agents teriparatide (Forteo), abaloparatide (Tymlos), romosozumab (Evenity) |
Stimulate new bone formation rather than blocking breakdown | Teriparatide and abaloparatide are not associated with MRONJ — teriparatide has even been used to help treat it. Romosozumab has rare reported cases; timing is discussed with your physician. |
| Hormone-based therapy estrogen, raloxifene (Evista) |
Preserve bone through hormonal pathways | No MRONJ concern. No special surgical restrictions related to the medication. |
For the most common scenario I see — a healthy patient taking a weekly alendronate pill for two or three years — the published MRONJ risk after oral surgery sits far below one percent. To put that in perspective, it is considerably lower than the baseline risk of ordinary implant failure from all other causes, which I wrote about in my guide to dental implant failure. The risk deserves respect and informed consent. It does not deserve the paralysis it often causes.
Factors That Raise MRONJ Risk
Duration of antiresorptive use beyond about four years, IV rather than oral dosing, cancer-level doses, concurrent corticosteroids (like prednisone), poorly controlled diabetes, smoking, active periodontal infection, and denture trauma. Notice how many of those are modifiable — which is exactly where good planning focuses.
Should You Stop Your Medication Before Surgery? The Drug Holiday Debate
Patients frequently arrive having already stopped their Fosamax "to be safe." I understand the instinct, but please do not do this on your own. The logic of a short drug holiday is weaker than it sounds, for a simple pharmacologic reason: bisphosphonates bind into your bone mineral and stay there for years. Pausing the pills for two months before surgery does almost nothing to change the drug already sitting in your jaw. Current guidance from the oral surgery community reflects this — there is no strong evidence that short drug holidays reduce MRONJ risk for osteoporosis-dose patients, and the decision is explicitly assigned to the prescribing physician and surgeon together, not to the patient or the dentist alone.
Meanwhile, the cost of stopping is not zero. Interrupting osteoporosis treatment raises fracture risk, and a hip fracture in your seventies is a far graver event than the small MRONJ risk the holiday was meant to address. With denosumab the stakes are even sharper: stopping it abruptly triggers rebound bone loss and a documented spike in vertebral fractures. The right move with Prolia is not stopping — it is timing, placing surgery in the window several months after the last injection when bone turnover suppression is at its lowest, then resuming the schedule on time.
You may also read about a blood test called serum CTX that was once promoted to predict MRONJ risk. It has not held up — the evidence does not support it as a reliable individual predictor, and I do not base surgical decisions on it.
How I Plan Implants for Patients With Osteoporosis
Here is what actually happens when a patient with osteoporosis — medicated or not — comes to The Loft Dental Studio for implant treatment:
- A complete medication history, in detail. Which drug, what dose, oral or IV, and for exactly how long — including past use, since bisphosphonates linger in bone long after the last pill. If anything is unclear, I call the prescribing physician. This coordination is not a formality; it is the plan.
- 3D CBCT imaging to assess bone quality, not just quantity. A cone-beam CT shows me the density and architecture of the exact site where the implant will go. Bone quality varies enormously within one jaw, and the scan tells me whether a site needs a modified approach, a graft, or a sinus lift.
- Eliminate infection first. Active gum disease multiplies every risk on this page. Periodontal treatment precedes implant surgery, always — this is the "save teeth and maintain" philosophy applied in the right order.
- Gentle, bone-preserving surgical technique. In softer bone I prepare the site conservatively — undersizing the preparation so the implant compresses and condenses the surrounding bone as it seats, improving initial stability. Implant length, width, and thread design are chosen for the bone in front of me, not from a standard playbook.
- Biologic support for healing. I routinely use PRF (platelet-rich fibrin) — a concentrate made from the patient's own blood — to bathe the surgical site in growth factors. In a patient whose bone biology runs slower, giving healing every advantage makes sense. Where bone volume is deficient, bone regeneration techniques rebuild the site before or alongside implant placement.
- Patience before loading. Where a routine case might be restored in a few months, an osteoporotic site may get extra healing time before the final crown transmits full chewing force. Slower is safer, and the finished result lasts just as long.
- Lifelong maintenance. Implants in every patient — and especially these patients — need regular professional monitoring to catch peri-implantitis early. Well-maintained implants routinely serve for decades, as I detailed in how long dental implants last.
When I Say No — or Not Yet
Honesty requires naming the situations where I pump the brakes. I generally do not place elective implants in patients receiving high-dose IV antiresorptives for cancer; the MRONJ risk there is orders of magnitude higher, and those patients deserve tooth-preservation strategies instead. I delay surgery when periodontal infection is uncontrolled, when diabetes is poorly managed, or when a patient on long-term antiresorptives also takes daily corticosteroids — a combination that stacks risk. And I slow down for heavy smokers, since smoking independently doubles implant failure risk and compounds everything else on this page. None of these is a permanent no. Most are a "let's fix this first."
The Bottom Line
Osteoporosis is one of the most over-feared diagnoses in implant dentistry. The evidence says osteoporotic patients enjoy implant success rates close to everyone else's when treatment is planned intelligently — and the medication questions that genuinely matter have clear, manageable answers: know the drug, know the duration, coordinate with the physician, time surgery wisely, never stop medication unilaterally, and respect the healing biology with gentle technique and patience.
If you have osteoporosis and have been told — by a dentist, a friend, or an internet forum — that implants are off the table for you, that deserves a second look from someone who treats these cases regularly. Bring your medication list. The conversation is almost always more encouraging than you expect.
